Autolus Therapeutics (NASDAQ:AUTL) Releases Quarterly Earnings Results, Meets Expectations

Autolus Therapeutics (NASDAQ:AUTL) issued its quarterly earnings results on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21), FiscalAI reports. Autolus Therapeutics had a negative net margin of 186.37% and a negative return on equity of 212.38%. The company had revenue of $41.24 million during the quarter, compared to analyst estimates of $39.54 million. During the same quarter last year, the business posted ($0.30) EPS.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• AUCATZYL revenue accelerated: Q3 net product revenue rose 95% year over year to $41.2 million, and Autolus now expects full-year 2026 revenue of at least $150 million, above its prior guidance range.
• Commercial reach expanded ahead of plan, with 90 U.S. centers authorized against an 80-center goal and 18 centers authorized in the U.K.; management said the U.K. launch is going well.
• Gross margin improved to 57% in Q3 and 44% year to date. Management attributed the gains to higher production volumes and manufacturing efficiencies, saying the company expects continued gradual improvement.
• Cash, cash equivalents, and marketable securities totaled $248.4 million at quarter-end; the company expects funding into Q2 2028, assuming anticipated AUCATZYL sales and $25 million from the second tranche of its credit facility. Q3 net loss was $55.1 million.
• Autolus moved its first BOBCAT progressive MS data presentation to October 2027 to allow longer follow-up, citing expert feedback that at least 12 months is needed to assess clinical outcomes. Management said the study remains on track, but the data update will come later than previously anticipated.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL traded down $0.02 during midday trading on Thursday, hitting $1.22. The company’s stock had a trading volume of 1,136,487 shares, compared to its average volume of 1,859,883. The firm has a market capitalization of $323.38 million, a price-to-earnings ratio of -1.25 and a beta of 2.32. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04. The stock has a fifty day moving average price of $1.74 and a 200 day moving average price of $1.66. Autolus Therapeutics has a one year low of $1.12 and a one year high of $2.58.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. HC Wainwright reissued a “buy” rating on shares of Autolus Therapeutics in a research report on Wednesday. UBS Group reaffirmed a “buy” rating on shares of Autolus Therapeutics in a research report on Wednesday. Weiss Ratings downgraded Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 3rd. Finally, Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient’s T cells to recognize and attack specific cancer cells, using the company’s proprietary cell-engineering technology. The company’s lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.